LOAD MORE
You're viewed all 11 products
Cefadroxil
References
FAQ's
References
- Crast, Leonard B., Jr.; Gottstein, William J., “Production of p-hydroxy cephalexin”, Bristol-Myers Co., United States, US3985741A, October 12, 1976
- Lindgren, Klas, “Determination of cefadroxil in serum by high-performance liquid chromatography with cephradine as internal standard”, Journal of Chromatography, Biomedical Applications, Volume: 413, Pages: 347-50, 1987
- Hsu, Mei-Chich; Chang, Ya-Wen; Lee, Yu-Tzer,”Column liquid chromatography and microbiological assay compared for determination of cefadroxil preparations”, Journal of Chromatography, Volume: 609, Issue: 1-2, Pages: 181-6, 1992
Frequently Asked Questions
What analytical methods are used for the detection of Cefadroxil impurities?
The analytical methods used for the detection of impurities in Cefadroxil include high-performance liquid chromatography (HPLC), liquid chromatography mass spectrometry (LC-MS), etc.
How can Cefadroxil impurities affect drug safety?
Impurities in Cefadroxil can affect its safety by causing adverse effects in patients, such as allergic reactions, toxicity, and organ damage.
How can Cefadroxil impurities affect the bioavailability of the drug?
Impurities in Cefadroxil can affect the bioavailability of the drug by altering its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion.
How can Cefadroxil impurities be removed?
The removal of Impurities in Cefadroxil may be by various purification techniques, such as recrystallization, column chromatography, and preparative HPLC.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.